Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amryt Pharma

Filsuvez's European Approval Adds Growth Driver For Amryt Pharma

Yesterday, Amryt Pharma plc (NASDAQ:AMYT) received European approval for Filsuvez for partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients six months and older. Filsuvez becomes the first approved treatment for EB. HC Wainwright notes that the Medicines and Healthcare products Regulatory Agency in the U.K. is expected to grant authorization…

Benzinga · Jun 24, 2022

Recap: Amryt Pharma Q1 Earnings

Recap: Amryt Pharma Q1 Earnings

Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients

Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients

Amryt Pharma Plc (NASDAQ: AMYT) has

Benzinga · Apr 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus

Amryt Pharma Plc's (NASDAQ:AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin revenues that increased 44% to $31.9 million. Cash of $113 million at December 31, 2021 (2020: $118.8M) The Company reported a wider operating loss of $(50.5) million…

Benzinga · Mar 9, 2022

Recap: Amryt Pharma Q4 Earnings

Amryt Pharma (NASDAQ:AMYT) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 9, 2022

A Preview Of Amryt Pharma's Earnings

Amryt Pharma (NASDAQ:AMYT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement. Analysts estimate that Amryt Pharma will report an earnings per share (EPS) of $-0.15.

Benzinga · Mar 8, 2022

FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder

Amryt Pharma Plc (NASDAQ: AMYT) has

Benzinga · Feb 28, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Coverage From

Benzinga

Organisations

Medicines and Healthcare products Regulatory Agency

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play